Embla Medical hf.

CPSE:EMBLA Rapporto sulle azioni

Cap. di mercato: DKK 11.2b

Embla Medical hf Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Sveinn Solvason

Amministratore delegato

US$1.0m

Compenso totale

Percentuale dello stipendio del CEO56.9%
Mandato del CEO3yrs
Proprietà del CEO0.02%
Durata media del management1.8yrs
Durata media del Consiglio di amministrazione10.2yrs

Aggiornamenti recenti sulla gestione

Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year

Mar 06
Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Apr 11
Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Here's Why Embla Medical hf (CPH:EMBLA) Can Manage Its Debt Responsibly

Mar 27
Here's Why Embla Medical hf (CPH:EMBLA) Can Manage Its Debt Responsibly

Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year

Mar 06
Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year

Investors Met With Slowing Returns on Capital At Embla Medical hf (CPH:EMBLA)

Feb 23
Investors Met With Slowing Returns on Capital At Embla Medical hf (CPH:EMBLA)
author-image

Acquisition Of Fior & Gentz And New Product Launches Will Expand Neuro Orthotics Portfolio Into New Markets

Feb 09 Expansion into new markets with Fior & Gentz acquisition could boost revenue and market share through neuro orthotics.

Embla Medical hf. Just Missed EPS By 5.8%: Here's What Analysts Think Will Happen Next

Feb 09
Embla Medical hf. Just Missed EPS By 5.8%: Here's What Analysts Think Will Happen Next

A Look At The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Jan 25
A Look At The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

We Ran A Stock Scan For Earnings Growth And Embla Medical hf (CPH:EMBLA) Passed With Ease

Jan 03
We Ran A Stock Scan For Earnings Growth And Embla Medical hf (CPH:EMBLA) Passed With Ease

Shareholders Should Be Pleased With Embla Medical hf.'s (CPH:EMBLA) Price

Dec 16
Shareholders Should Be Pleased With Embla Medical hf.'s (CPH:EMBLA) Price

Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly

Nov 30
Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 25
Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Oct 17
Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Oct 02
Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Aug 22
Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26
Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17
Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14
Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26
Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Apr 10
A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Mar 23
Is Össur hf (CPH:OSSR) Using Too Much Debt?

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Jan 21
Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 03
Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Nov 28
Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Nov 08
Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

Sep 23
A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Aug 21
We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Jul 18
Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 14
Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

May 19
Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Mar 14
Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 21
A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22
These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07
There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21
Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02
Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16
Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16
Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01
Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08
Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22
Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03
Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25
Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Sveinn Solvason rispetto agli utili di Embla Medical hf?
DataCompenso totaleStipendioGuadagni aziendali
Dec 31 2024US$1mUS$576k

US$68m

Sep 30 2024n/an/a

US$69m

Jun 30 2024n/an/a

US$61m

Mar 31 2024n/an/a

US$57m

Dec 31 2023US$1mUS$576k

US$58m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$45m

Mar 31 2023n/an/a

US$43m

Dec 31 2022US$780kUS$409k

US$43m

Compensazione vs Mercato: La retribuzione totale di Sveinn ($USD 1.01M ) è inferiore alla media delle aziende di dimensioni simili nel mercato Danish ($USD 2.75M ).

Compensazione vs guadagni: La retribuzione di Sveinn è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Sveinn Solvason (46 yo)

3yrs

Mandato

US$1,013,000

Compensazione

Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Sveinn Solvason
President & CEO3yrsUS$1.01m0.016%
DKK 1.8m
Ossur Kristinsson
Founderno dataUS$25.00kNessun dato
Gudny Sveinsdottir
Chief Financial Officer2.6yrsNessun datoNessun dato
Lukas Marklin
Chief Operating Officer1.8yrsNessun datoNessun dato
Klaus Sindahl
Head of Investor Relationsno dataNessun datoNessun dato
Edda H. Geirsdottir
VP of Corporate Communicationsno dataNessun datoNessun dato
Margret Fridriksdottir
Executive Vice President of Peopleno dataUS$242.00k0.0083%
DKK 930.9k
Olafur Gylfason
Executive Vice President of Chronic Solutionsno dataUS$600.00k0.0077%
DKK 863.5k
Christian Robinson
President Americas & Global Bracingno dataNessun dato0.0031%
DKK 348.1k
Andre Rocha
Executive Vice President of Research & Developmentless than a yearNessun datoNessun dato
Conal Harte
EVP of Patient Careless than a yearNessun datoNessun dato
Edda Luovigsdottir
Investor Relations Directorno dataNessun datoNessun dato

1.8yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di EMBLA non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Niels Jacobsen
Chairman of the Board20.3yrsUS$111.00k0%
DKK 0
Svafa Gronfeldt
Vice Chairman of the Board17.3yrsUS$74.00kNessun dato
Caroline Rosenstand
Independent Director1.1yrsUS$44.00kNessun dato
Arne Nielsen
Director16.3yrsUS$52.00kNessun dato
Alberto Esquenazi
Independent Director4.1yrsUS$44.00kNessun dato
Tina Olesen
Independent Director1.1yrsUS$37.00kNessun dato

10.2yrs

Durata media

57.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di EMBLA è composto da personale esperto e esperto (durata media dell'incarico 10.2 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/04/19 11:51
Prezzo dell'azione a fine giornata2025/04/16 00:00
Guadagni2024/12/31
Guadagni annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Embla Medical hf. è coperta da 10 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullABG Sundal Collier
null nullABG Sundal Collier Sponsored
Niels Granholm-LethCarnegie Investment Bank AB